A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy

Inclusion Criteria

Inclusion criteria;

- Participant has been diagnosed with an STM or HM and is not likely to undergo
hematopoietic cell transplant (HCT) and:

- Participant is ≥18 years of age and receiving a cytotoxic or immunosuppressive
chemotherapy regimen

- Participant is ≥ 50 years of age with a hematologic malignancy that is not in
remission, whether on therapy or not

- Participant has a life expectancy ≥ 12 months.

- Participant has prior history of varicella or antibodies to VZV due to exposure to
the disease in a country where the disease is common.

Exclusion criteria:

- Participant has a history of allergic reaction to any vaccine component (including
gelatin) or an anaphylactic/anaphylactoid reaction to neomycin.

- Participant has a prior history of HZ within 1 year of enrollment.

- Participant has received or is expected to receive any varicella or non-study zoster
vaccine.

- Participant is currently receiving or expected to receive long-term antiviral
prophylaxis (>4 weeks duration) with activity against herpes simplex virus (HSV), VZV
or cytomegalovirus (CMV)

- Participant is pregnant or breastfeeding or expecting to conceive within the period
of 2 weeks prior to enrollment throughout 6 months after last vaccination dose.

- Participant has had any live virus vaccine administered or scheduled in the period
from 4 weeks prior to Dose 1 through 28 days post vaccination dose 4

- Participant has had inactivated vaccine administered or scheduled within the period
from 7 days prior to, through 7 days following, any dose of study vaccine.